当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Eighteen 5,7-Dihalo-8-quinolinol and 2,2'-Bipyridine Co(II) Complexes as a New Class of Promising Anticancer Agents.
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2019-10-30 , DOI: 10.1021/acsmedchemlett.9b00356
Ting Meng 1 , Qi-Pin Qin 1, 2 , Hua-Hong Zou 1 , Kai Wang 1, 3 , Fu-Pei Liang 1, 3
Affiliation  

Here we first report the design of a series of bis-chelate Co(II) 5,7-dihalo-8-quinolinol-phenanthroline derivative complexes, [Co(py)(QL1)2] (Co1), [Co(py)(QL2)2] (Co2), [Co(Phen)(QL1)2] (Co3), [Co(Phen)(QL2)2] (Co4), [Co(DPQ)(QL1)2]·(CH3OH)4 (Co5), [Co(DPQ)(QL2)2] (Co6), [Co(DPPZ)(QL1)2]·CH3OH (Co7), [Co(MDP)(QL1)2]·3H2O (Co8), [Co(ODP)(QL1)2]·CH3OH (Co9), [Co(PPT)(QL1)2]·CH3OH (Co10), [Co(ClPT)(QL1)2] (Co11), [Co(dpy)(QL3)2] (Co12), [Co(mpy)(QL1)2] (Co13), [Co(Phen)(QL4)2] (Co14), [Co(ODP)(QL4)2] (Co15), [Co(mpy)(QL4)2]I (Co16), [Co(ClPT)(QL4)2] (Co17), and [Co(ClPT)(QL5)2] (Co18), with 5,7-dihalo-8-quinolinol and 2,2'-bipyridine mixed ligands. The antitumor activity of Co1-Co18 has been evaluated against human HeLa (cervical) cancer cells in vitro (IC50 values = 0.8 nM-11.88 μM), as well as in vivo against HeLa xenograft tumor growth (TIR = 43.7%, p < 0.05). Importantly, Co7 exhibited high safety in vivo and was more effective in inhibiting HeLa tumor xenograft growth (43.7%) than cisplatin (35.2%) under the same conditions (2.0 mg/kg). In contrast, the H-QL1 and DPPZ ligands greatly enhanced the activity and selectivity of Co7 in comparison to Co1-Co6, Co8-Co18, and previously reported cobalt(II) compounds. In addition, Co7 (0.8 nM) inhibited telomerase activity, caused G2/M phase arrest, and induced mitochondrial dysfunction at a concentration 5662.5 times lower than Co1 (4.53 μM) in related assays. Taken together, Co7 showed low toxicity, and the combination could be a novel Co(II) antitumor compound candidate.

中文翻译:

十八种5,7-二卤-8-喹啉醇和2,2'-联吡啶Co(II)配合物是一类新的有前途的抗癌药物。

在这里,我们首先报告一系列双螯合物Co(II)5,7-二卤代-8-喹啉醇-菲咯啉衍生物配合物[Co(py)(QL1)2](Co1),[Co(py) (QL2)2](Co2),[Co(Phen)(QL1)2](Co3),[Co(Phen)(QL2)2](Co4),[Co(DPQ)(QL1)2]·(CH3OH )4(Co5),[Co(DPQ)(QL2)2](Co6),[Co(DPPZ)(QL1)2]·CH3OH(Co7),[Co(MDP)(QL1)2]·3H2O(Co8 ),[Co(ODP)(QL1)2]·CH3OH(Co9),[Co(PPT)(QL1)2]·CH3OH(Co10),[Co(ClPT)(QL1)2](Co11),[Co (dpy)(QL3)2](Co12),[Co(mpy)(QL1)2](Co13),[Co(Phen)(QL4)2](Co14),[Co(ODP)(QL4)2] (Co15),[Co(mpy)(QL4)2] I(Co16),[Co(ClPT)(QL4)2](Co17)和[Co(ClPT)(QL5)2](Co18),其中5 ,7-二卤代-8-喹啉醇和2,2'-联吡啶混合的配体。已评估了Co1-Co18在体外对人HeLa(宫颈)癌细胞的抗肿瘤活性(IC50值= 0.8 nM-11.88μM),以及体内抗HeLa异种移植肿瘤的生长(TIR = 43.7%,p <0.05)。重要的是,在相同条件下(2.0 mg / kg),Co7在体内显示出很高的安全性,并且在抑制HeLa肿瘤异种移植物生长方面(43.7%)比顺铂(35.2%)更有效。相反,与Co1-Co6,Co8-Co18和先前报道的钴(II)化合物相比,H-QL1和DPPZ配体大大提高了Co7的活性和选择性。此外,在相关试验中,Co7(0.8 nM)抑制端粒酶活性,引起G2 / M期停滞,并诱导线粒体功能障碍,其浓度比Co1(4.53μM)低5662.5倍。两者合计,Co7显示低毒性,并且该组合可能是一种新型的Co(II)抗肿瘤化合物候选物。在相同条件下(2.0 mg / kg),Co7在体内显示出高安全性,并且在抑制HeLa肿瘤异种移植物生长方面(43.7%)比顺铂(35.2%)更有效。相反,与Co1-Co6,Co8-Co18和先前报道的钴(II)化合物相比,H-QL1和DPPZ配体大大提高了Co7的活性和选择性。此外,在相关试验中,Co7(0.8 nM)抑制端粒酶活性,引起G2 / M期停滞,并诱导线粒体功能障碍,其浓度比Co1(4.53μM)低5662.5倍。两者合计,Co7显示低毒性,并且该组合可能是一种新型的Co(II)抗肿瘤化合物候选物。在相同条件下(2.0 mg / kg),Co7在体内显示出高安全性,并且在抑制HeLa肿瘤异种移植物生长方面(43.7%)比顺铂(35.2%)更有效。相反,与Co1-Co6,Co8-Co18和先前报道的钴(II)化合物相比,H-QL1和DPPZ配体大大提高了Co7的活性和选择性。此外,在相关试验中,Co7(0.8 nM)抑制端粒酶活性,引起G2 / M期停滞,并诱导线粒体功能障碍,其浓度比Co1(4.53μM)低5662.5倍。两者合计,Co7显示低毒性,并且该组合可能是一种新型的Co(II)抗肿瘤化合物候选物。与Co1-Co6,Co8-Co18和先前报道的钴(II)化合物相比,H-QL1和DPPZ配体大大提高了Co7的活性和选择性。此外,在相关试验中,Co7(0.8 nM)抑制端粒酶活性,引起G2 / M期停滞,并诱导线粒体功能障碍,其浓度比Co1(4.53μM)低5662.5倍。两者合计,Co7显示低毒性,并且该组合可能是一种新型的Co(II)抗肿瘤化合物候选物。与Co1-Co6,Co8-Co18和先前报道的钴(II)化合物相比,H-QL1和DPPZ配体大大提高了Co7的活性和选择性。此外,在相关试验中,Co7(0.8 nM)抑制端粒酶活性,引起G2 / M期停滞,并诱导线粒体功能障碍,其浓度比Co1(4.53μM)低5662.5倍。两者合计,Co7显示低毒性,并且该组合可能是一种新型的Co(II)抗肿瘤化合物候选物。
更新日期:2019-11-11
down
wechat
bug